Deep vein thrombosis

References

Key articles

National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020 [internet publication].Full text

Kakkos SK, Gohel M, Baekgaard N, et al. Editor's choice: European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82.Full text  Abstract

Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J. 2018 Dec 14;39(47):4208-18.Full text  Abstract

National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. August 2019 [internet publication].Full text

Reference articles

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001 Jul;86(1):452-63. Abstract

2. White RH. The epidemiology of venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8.Full text  Abstract

3. White RH, Zhou H, Murin S, et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005 Feb;93(2):298-305. Abstract

4. James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2009:277-85.Full text  Abstract

5. Dentali F, Mumoli N, Prisco D, et al. Efficacy and safety of extended thromboprophylaxis for medically ill patients: a meta-analysis of randomised controlled trials. Thromb Haemost. 2017 Feb 28;117(3):606-17. Abstract

6. Kaplan D, Casper TC, Elliott CG, et al. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015 Nov;148(5):1224-30.Full text  Abstract

7. Marder VJ, Rosove MH, Minning DM. Foundation and sites of action of antithrombotic agents. Best Pract Res Clin Haematol. 2004 Mar;17(1):3-22. Abstract

8. Geddings JE, Mackman N. Tumor derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013 Sep 12;122(11):1873-80.Full text  Abstract

9. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-7.Full text  Abstract

10. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis. 2008 Feb;25(1):37-44. Abstract

11. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016 Jul;14(7):1480-3.Full text  Abstract

12. National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020 [internet publication].Full text

13. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603.Full text  Abstract

14. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002 Oct 19;325(7369):887-90.Full text  Abstract

15. Cogo A, Lensing AW, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep vein thrombosis: implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993 Dec 27;153(24):2777-80. Abstract

16. Kearon C, Ginsberg JS, Douketis J, et al. A new and improved system for excluding the diagnosis of deep venous thrombosis. Ann Intern Med. 2001;135:S-24. Abstract

17. Bates SM, Jaeschke R, Stevens SM, et al; American College of Chest Physicians. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis (9th ed): American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e351S-418S.Full text  Abstract

18. Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol. 2011 Jan;152(1):31-4.Full text  Abstract

19. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44.Full text  Abstract

20. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. Abstract

21. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77.Full text  Abstract

22. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23.Full text  Abstract

23. Chopra V, Flanders SA, Saint S, et al. The Michigan appropriateness guide for intravenous catheters (MAGIC): results from a multispecialty panel using the RAND/UCLA appropriateness method. Ann Intern Med. 2015 Sep 15;163(suppl 6):S1-40. Abstract

24. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22. Abstract

25. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007 May;62(2):126-36. Abstract

26. Kakkos SK, Gohel M, Baekgaard N, et al. Editor's choice: European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82.Full text  Abstract

27. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J. 2018 Dec 14;39(47):4208-18.Full text  Abstract

28. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010 Oct 25;170(19):1710-6.Full text  Abstract

29. Ekeh AP, Dominguez KM, Markert RJ, et al. Incidence and risk factors for deep venous thrombosis after moderate and severe brain injury. J Trauma. 2010 Apr;68(4):912-5. Abstract

30. Paffrath T, Wafaisade A, Lefering R, et al. Venous thromboembolism after severe trauma: incidence, risk factors and outcome. Injury. 2010 Jan;41(1):97-101. Abstract

31. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003 Sep;90(3):446-55. Abstract

32. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019 Feb 1;4(2):163-73.Full text  Abstract

33. Martínez-Zamora MÁ, Cervera R, Balasch J. Thromboembolism risk following recurrent miscarriage. Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1503-13. Abstract

34. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005 Nov 15;143(10):697-706. Abstract

35. Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008 Apr;6(4):632-7.Full text  Abstract

36. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005 Jul;94(1):17-25. Abstract

37. Hirmerova J, Seidlerova J, Subrt I. The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox. QJM. 2014 Sep;107(9):715-20. Abstract

38. Croles FN, Nasserinejad K, Duvekot JJ, et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017 Oct 26;359:j4452.Full text  Abstract

39. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.Full text  Abstract

40. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018 May 24;378(21):2010-21. Abstract

41. Ortel TL. Thrombosis and the antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2005:462-8.Full text  Abstract

42. Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004 Jul 1;104(1):143-8.Full text  Abstract

43. Barba R, Gonzalvez-Gasch A, Joya Seijo D, et al. Venous thromboembolism in patients with liver diseases. J Thromb Haemost. 2018 Oct;16(10):2003-7. Abstract

44. Ho KM, Bham E, Pavey W. Incidence of venous thromboembolism and benefits and risks of thromboprophylaxis after cardiac surgery: a systematic review and meta-analysis. J Am Heart Assoc. 2015 Oct 26;4(10):e002652.Full text  Abstract

45. Cook D, Attia J, Weaver B, et al. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care. 2000 Dec;15(4):127-32. Abstract

46. Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015 Nov;100(11):4012-20.Full text  Abstract

47. Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008 May 31;336(7655):1227-31.Full text  Abstract

48. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004 Oct 11;164(18):1965-76.Full text  Abstract

49. Committee on Gynecologic Practice. ACOG committee opinion number 540: risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Obstet Gynecol. 2012 Nov;120(5):1239-42. Abstract

50. Angelini D, Khorana AA. Risk assessment scores for cancer-associated venous thromboembolic disease. Semin Thromb Hemost. 2017 Jul;43(5):469-78. Abstract

51. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011 Apr;63(4):877-83.Full text  Abstract

52. Guo Z, Huang Y, Gong L, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):451-60. Abstract

53. Walker RF, Zakai NA, MacLehose RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020 Feb 1;180(2):190-7.Full text  Abstract

54. Schmidt M, Christiansen CF, Horváth-Puhó E, et al. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011 Jul;9(7):1326-33.Full text  Abstract

55. Ungprasert P, Srivali N, Wijarnpreecha K, et al. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford). 2015 Apr;54(4):736-42.Full text  Abstract

56. Turpie AG, Chin BS, Lip GY. ABC of antithrombotic therapy: venous thromboembolism - treatment strategies. BMJ. 2002 Oct 26;325(7370):948-50.Full text  Abstract

57. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-226S.Full text  Abstract

58. Sindet-Pedersen C, Bruun Oestergaard L, Gundlund A, et al. Familial clustering of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2016 Dec 29;11(12):e0169055.Full text  Abstract

59. National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. August 2019 [internet publication].Full text

60. National Institute for Health and Care Excellence. Venous thromboembolism in adults. August 2021 [internet publication].Full text

61. Stuck AK, Spirk D, Schaudt J, et al. Risk assessment models for venous thromboembolism in acutely ill medical patients: a systematic review. Thromb Haemost. 2017 Apr 3;117(4):801-8. Abstract

62. Gibson CM, Spyropoulos AC, Cohen AT, et al. The IMPROVEDD VTE risk score: incorporation of D-Dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open. 2017 Jun;1(1):e56-65.Full text  Abstract

63. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e278S-325S.Full text  Abstract

64. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75.Full text  Abstract

65. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr;105(4):721-9. Abstract

66. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85.Full text  Abstract

67. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. Abstract

68. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Abstract

69. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86.Full text  Abstract

70. RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. Abstract

71. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Abstract

72. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604.Full text  Abstract

73. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. Abstract

74. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98.Full text  Abstract

75. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2018 Dec 4;380(8):711-9.Full text  Abstract

76. Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021 Mar 29;(3):CD001689.Full text  Abstract

77. Shalhoub J, Lawton R, Hudson J, et al. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ. 2020 May 13;369:m1309.Full text  Abstract

78. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-27.Full text  Abstract

79. Bajaj NS, Vaduganathan M, Qamar A, et al. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: a trial sequential and cumulative meta-analysis. PLoS Med. 2019 Apr;16(4):e1002797.Full text  Abstract

80. Czuprynska J, Arya R. Annotation: travel and thrombosis. Br J Haematol. 2020 Mar;188(6):838-43.Full text  Abstract

81. Cooper RM, Hayat SA. Phlegmasia cerulea dolens, a rare complication of deep vein thrombosis. Emerg Med J. 2008 Jun;25(6):334. Abstract

82. Chaochankit W, Akaraborworn O. Phlegmasia cerulea dolens with compartment syndrome. Ann Vasc Dis. 2018 Sep 25;11(3):355-7.Full text  Abstract

83. Stubbs MJ, Mouyis M, Thomas M. Deep vein thrombosis. BMJ. 2018 Feb 22;360:k351. Abstract

84. Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ. 2003 May 31;326(7400):1180-4.Full text  Abstract

85. Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006 Jan 28;332(7535):215-9.Full text  Abstract

86. Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ. 2006 Oct 24;175(9):1087-92.Full text  Abstract

87. Jain N, Avanthika C, Singh A, et al. Deep vein thrombosis in intravenous drug users: an invisible global health burden. Cureus. 2021 Oct;13(10):e18457.Full text  Abstract

88. Hasegawa M, Wada H, Yamaguchi T, et al. The evaluation of D-dimer levels for the comparison of fibrinogen and fibrin units using different D-dimer kits to diagnose VTE. Clin Appl Thromb Hemost. 2018 May;24(4):655-62. Abstract

89. Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008 Oct 8;300(14):1653-9.Full text  Abstract

90. Remy-Jardin M, Remy J, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology. 1996 Sep;200(3):699-706. Abstract

91. Chan WS, Spencer FA, Ginsbergm JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ. 2010 Apr 20;182(7):657-60.Full text  Abstract

92. Francalanci I, Comeglio P, Liotta AA, et al. D-dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res. 1995 Jun 1;78(5):399-405. Abstract

93. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 Sep 5;122(10):1712-23.Full text  Abstract

94. DI Nisio M, Otten HM, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost. 2005 Nov;3(11):2391-6.Full text  Abstract

95. Van Doormaal FF, Terpstra W, Van Der Griend R, et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost. 2011 Jan;9(1):79-84.Full text  Abstract

96. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016 Jan;41(1):154-64.Full text  Abstract

97. Gorman WP, Davis KR, Donnelly R. ABC of arterial and venous disease. Swollen lower limb-1: general assessment and deep vein thrombosis. BMJ. 2000 May 27;320(7247):1453-6.Full text  Abstract

98. White RH, McGahan JP, Daschbach MM, et al. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med. 1989 Aug 15;111(4):297-304. Abstract

99. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003 Mar;2(2):148-57. Abstract

100. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007 Jan-Feb;5(1):63-73.Full text  Abstract

101. Haut ER, Schneider EB, Patel A, et al. Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices. J Trauma. 2011 Jan;70(1):27-33. Abstract

102. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e227S-77S.Full text  Abstract

103. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018 Jan 9;(1):CD003076.Full text  Abstract

104. Howard LSGE, Barden S, Condliffe R, et al. British Thoracic Society guideline for the initial outpatient management of pulmonary embolism (PE). Thorax. 2018 Jul;73(suppl 2):ii1-29.Full text  Abstract

105. Chinsakchai K, Ten Duis K, Moll FL, et al. Trends in management of phlegmasia cerulea dolens. Vasc Endovascular Surg. 2011 Jan;45(1):5-14. Abstract

106. Patel NH, Plorde JJ, Meissner M. Catheter-directed thrombolysis in the treatment of phlegmasia cerulea dolens. Ann Vasc Surg. 1998 Sep;12(5):471-5. Abstract

107. Zhang X, Chen Z, Sun Y, et al. Surgical thrombectomy and simultaneous stenting for phlegmasia cerulea dolens caused by iliac vein occlusion. Ann Vasc Surg. 2018 Aug;51:239-45. Abstract

108. National Institute for Health and Care Excellence. Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg. June 2019 [internet publication].Full text

109. National Institute for Health and Care Excellence. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis. June 2015 [internet publication].Full text

110. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510.Full text  Abstract

111. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52.Full text  Abstract

112. International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753-64.Full text  Abstract

113. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 Nov 27;116(22):2563-70. Abstract

114. Kheiri B, Abdalla A, Haykal T, et al. Meta-analysis of genotype-guided versus standard dosing of vitamin K antagonists. Am J Cardiol. 2018 Apr 1;121(7):879-87. Abstract

115. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013 Dec 12;369(24):2304-12.Full text  Abstract

116. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 Dec 12;369(24):2294-303.Full text  Abstract

117. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 Dec 12;369(24):2283-93.Full text  Abstract

118. Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing: recalibrating expectations. N Engl J Med. 2013 Dec 12;369(24):2273-5. Abstract

119. Ageno W, Beyer-Westendorf J, Garcia DA, et al. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016 Jan;41(1):129-43.Full text  Abstract

120. Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Aug;19(8):1874-82.Full text  Abstract

121. Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(22):1670-80.Full text  Abstract

122. National Institute for Health and Care Excellence. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. June 2015 [internet publication].Full text

123. Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: acute management. Green-top guideline no. 37b. April 2015 [internet publication].Full text

124. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011 Feb 24;342:d813.Full text  Abstract

125. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010 Oct 19;153(8):523-31. Abstract

126. Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014 Jul 10;124(2):196-203.Full text  Abstract

127. Kearon C, Spencer FA, O'Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015 Jan 6;162(1):27-34. Abstract

128. Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost. 2012 Dec;108(6):1061-4. Abstract

129. Rodger MA, Le Gal G, Anderson DR; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017 Mar 17;356:j1065.Full text  Abstract

130. Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021 Dec;160(6):e545-608.Full text  Abstract

131. Appelen D, van Loo E, Prins MH, et al. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev. 2017 Sep 26;(9):CD004174.Full text  Abstract

132. Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: a systematic review. Thromb Res. 2008;122(6):763-73. Abstract

133. Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, et al. Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. Int Angiol. 2008 Dec;27(6):494-9. Abstract

134. Aissaoui N, Martins E, Mouly S, et al. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. Int J Cardiol. 2009 Sep 11;137(1):37-41. Abstract

135. Anderson CM, Overend TJ, Godwin J, et al. Ambulation after deep vein thrombosis: a systematic review. Physiother Can. 2009 Summer;61(3):133-40.Full text  Abstract

136. Expert Panel on Interventional Radiology; Minocha J, Smith AM, Kapoor BS, et al. ACR Appropriateness Criteria® radiologic management of venous thromboembolism-inferior vena cava filters. J Am Coll Radiol. 2019 May;16(5s):S214-26.Full text  Abstract

137. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484-8.Full text  Abstract

138. Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015 Sep;136(3):582-9.Full text  Abstract

139. Medicines and Healthcare products Regulatory Agency. Rivaroxaban (Xarelto): reminder that 15 mg and 20 mg tablets should be taken with food. July 2019 [internet publication].Full text

140. Expert Panel on Interventional Radiology; Minocha J, Smith AM, Kapoor BS, et al. ACR Appropriateness Criteria® radiologic management of venous thromboembolism-inferior vena cava filters. J Am Coll Radiol. 2019 May;16(5s):S214-26Full text  Abstract

141. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-5Full text  Abstract

142. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433-41Full text  Abstract

143. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-60Full text  Abstract

144. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. December 2019 [internet publication]Full text

145. Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 Apr 2;74(1):101-7Full text  Abstract

146. NHS England. Toolkit for general practice in supporting older people living with frailty. March 2017 [internet publication]Full text

147. Wallis SJ, Wall J, Biram RW, et al. Association of the clinical frailty scale with hospital outcomes. QJM. 2015 Dec;108(12):943-9Full text  Abstract

148. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13 Abstract

149. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text  Abstract

150. The National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]Full text

151. Office of the Public Guardian. Mental Capacity Act: making decisions. October 2014 [internet publiction]Full text

152. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). January 2010 [internet publication]Full text

153. Joint British Diabetes Societies for inpatient care. The management of diabetic ketoacidosis in adults. June 2021 [internet publication]Full text

154. Joint British Diabetes Societies for inpatient care. The management of the hyperosmolar hyperglycaemic state (HHS) in adults. February 2022 [internet publication]Full text

155. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 Abstract

156. Joint British Diabetes Societies for inpatient care. Self-management of diabetes in hospital. August 2021 [internet publication]Full text

157. Joint British Diabetes Societies for inpatient care. Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes. November 2019 [internet publication]Full text

158. Joint British Diabetes Societies for inpatient care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. October 2014 [internet publication]Full text

159. Joint British Diabetes Societies for inpatient care. A good inpatient diabetes service. July 2019 [internet publication]Full text

160. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. March 2021 [internet publication]Full text

161. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88Full text  Abstract

162. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. March 2020 [internet publication]Full text

163. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38(9):1687-93 Abstract

164. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Nov 9;6(12):681-94 Abstract

165. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13 Abstract

166. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Full text  Abstract

167. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Oct 13;44(6):1000-5Full text  Abstract

168. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract

169. National Institute for Health and Care Excellence. Delirium: diagnosis, prevention and management. March 2019 [internet publication]Full text

170. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. June 2018 [internet publication]Full text

171. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium. March 2019 [internet publication]Full text

172. Nova Scotia Health Authority. This is not my Mom. 2012 [internet publication]Full text

173. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73 Abstract

174. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Mar 2;43(4):496-502Full text  Abstract

175. MacLullich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019 Aug;23(40):1-194Full text  Abstract

176. White S, Griffiths R, Baxter M, et al. Guidelines for the peri-operative care of people with dementia: guidelines from the Association of Anaesthetists. Anaesthesia. 2019 Jan 11;74(3):357-72Full text  Abstract

177. Siddiqi N, Harrison JK, Clegg A, et al. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016 Mar 11;3:CD005563Full text  Abstract

178. Martinez F, Tobar C, Hill N. Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age Ageing. 2014 Nov 25;44(2):196-204Full text  Abstract

179. Public Health England. Urinary tract infection: diagnostic tools for primary care. October 2020 [internet publication]Full text

180. Medicines and Healthcare products Regulatory Agency. Haloperidol (haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. 2021 [internet publication]Full text

181. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915-37 Abstract

182. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23;344:e977Full text  Abstract

183. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;3:CD007726Full text  Abstract

184. American Diabetes Association. 16. Diabetes care in the hospital: standards of medical care in diabetes - 2022. Diabetes Care. 2022 Jan 1;45(suppl 1):S244-S253.Full text  Abstract

185. Joint British Diabetes Societies for inpatient care. A good inpatient diabetes service. July 2019 [internet publication]Full text

186. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. March 2022 [internet publication]Full text

187. Joint British Diabetes Societies for inpatient care. Inpatient care of the frail older adult with diabetes. 2019 [internet publication]Full text

188. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67Full text  Abstract

189. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text  Abstract

190. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010 Mar;137(3):544-51Full text  Abstract

191. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8Full text

192. NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2019. Nov 2020 [internet publication]Full text

193. Joint British Diabetes Societies for inpatient care. The hospital management of hypoglycaemia in adults with diabetes mellitus. March 2022 [internet publication]Full text

194. TREND Diabetes. End of life guidance for diabetes care. November 2021 [internet publication]Full text

195. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication]Full text

196. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 May 18;34(7):1517-8Full text  Abstract

197. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text

198. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 [internet publication]Full text

199. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21Full text  Abstract

200. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51Full text  Abstract

201. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2022 [internet publication]Full text

202. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897Full text  Abstract

203. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2019 [internet publication]Full text

204. Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021 Nov;87(11):4051-100 Abstract

205. National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020 [internet publication]Full text

206. Kakkos SK, Gohel M, Baekgaard N, et al. Editor's choice: European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82Full text  Abstract

207. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018 Dec 14;39(47):4208-18Full text  Abstract

208. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May 12;29(5):459-525Full text  Abstract

209. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. 2009 [internet publication]Full text

210. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021

211. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20 Abstract

212. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 Abstract

213. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid. 2016 Jun;11(6)4-7Full text

214. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94 Abstract

215. Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17Full text  Abstract

216. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication]Full text

217. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13 Abstract

218. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 Mar 7;106(5):906-14Full text  Abstract

219. National Institute for Health and Care Excellence. Liaison psychiatry. In: Emergency acute medical care in over 16s: service delivery and organisation. March 2018 [internet publication]Full text

220. National Confidential Enquiry into Patient Outcome and Death (NCEPOD). Treat as one. Bridging the gap between mental and physical healthcare in general hospitals. 2017 [internet publication]Full text

221. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7 Abstract

222. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(7 suppl):S54-60 Abstract

223. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. October 2009 [internet publication]Full text

224. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2014 Nov 8;78(1):25-33Full text  Abstract

225. World Health Organization. Excess mortality in persons with severe mental disorders. 2016 [internet publication]Full text

226. Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10(9):e1001515Full text  Abstract

227. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. August 2022 [internet publication]Full text

228. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication]Full text

229. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-5Full text  Abstract

230. NHS Specialised Clinical Frailty Network. Clinical frailty scale. 2018 [internet publication]Full text

231. National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. August 2019 [internet publication]Full text

232. Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010 May 4;152(9):578-89. Abstract

233. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism: the Worcester VTE study. J Thromb Thrombolysis. 2009 Nov;28(4):401-9. Abstract

234. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000 Mar 27;160(6):761-8.Full text  Abstract

235. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995 Jun 22;332(25):1661-5. Abstract

236. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997 Feb 6;336(6):393-8. Abstract

237. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008 Dec 1;112(12):4432-6.Full text  Abstract

238. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 Nov;101(5):502-7. Abstract

239. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989 Mar;95(3):498-502. Abstract

240. Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005 Apr;3(4):718-23.Full text  Abstract

241. Galanaud JP, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. Thromb Res. 2018 Apr;164:100-9. Abstract

242. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999 Nov;107(5):414-24. Abstract

243. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016 Feb;24(1):6-46. Abstract

244. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep 10;128(11):1234-43. Abstract

245. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e44S-88S.Full text  Abstract

246. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015 Dec 17;373(25):2413-24.Full text  Abstract

247. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 suppl):e24-43S.Full text  Abstract

248. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994 Jan 10;154(1):49-56. Abstract

249. Lefkou E, Khamashta M, Hampson G, et al. Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus. 2010 Jan;19(1):3-12. Abstract

250. Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008 Jul;42(7):979-88. Abstract

251. INR self-monitoring and oral anticoagulants. Prescrire Int. 2010 Jun;19(107):130-2. Abstract

252. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64.Full text  Abstract

253. Wiggins BS, Dixon DL, Neyens RR, et al. Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol. 2020 Mar 24;75(11):1341-50.Full text  Abstract

254. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolis.m. Blood. 2014 Mar 20;123(12):1794-801.Full text  Abstract

Use of this content is subject to our disclaimer